Farmacy

Sep 25 2017

Promius Pharma Launches Sernivo™ (betamethasone Dipropionate) Spray, % #pharmaceutical #rep

#promius pharma # Promius Pharma Launches Sernivo™ (betamethasone Dipropionate) Spray, 0.05% Dr. Reddy’s Laboratories announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), launched Sernivo™ (betamethasone dipropionate) Spray, 0.05% in the U.S. Sernivo Spray, a prescription topical steroid approved by the Food and Drug Administration (FDA) in February of 2016, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. “We are proud to bring Sernivo Spray to patients across the U.S.,” said Raghav Chari, Executive Vice President, Proprietary Products Group at Dr. Reddy’s …

Sep 25 2017

Promius Pharma, LLC Company Information #pharmacy

#promius pharma # Promius Pharma, LLC Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page helpful? …

Sep 25 2017

DRL s arm Promius Pharma launches new brand identity – Times of India #pharmaceutical #company

#promius pharma # DRL’s arm Promius Pharma launches new brand identity Hyderabad-based pharma giant Dr Reddy’s Laboratories (DRL) on Thursday announced that its subsidiary Promius Pharma LLC has launched its new visual identity and corporate brand — The Power of Humans Being. It expresses the core belief at Promius Pharma that “every patient is a person first” and its mission to “help patients get back to what matters most—being a person,” the release said. Commenting on the brand launch, Promius Pharma chief commercial officer Anil Namboodiripad said, “Our new corporate brand identity clearly establishes Promius Pharma as a strong and …

Sep 25 2017

Promius Pharma Launches NoTime4Migraines, An Online Resource About Migraine Symptoms and Potential #jobs #in #pharmaceuticals

#promius pharma # Promius Pharma Launches NoTime4Migraines, An Online Resource About Migraine Symptoms and Potential Treatment Options PRINCETON, N.J. Aug. 24, 2016 /PRNewswire/ — Promius Pharma, LLC, today launched NoTime4Migraines. an online disease education resource for migraine patients that adds dimension to awareness with a social media presence on Facebook and Twitter . NoTime4Migraines helps patients recognize that their migraine attacks vary and offers ways to manage them. Its goal: empower patients to seek better control of migraine its symptoms and impact on everyday life at home, work, school, or in social settings. “Migraines are not just painful they can …

Sep 5 2017

Promius Pharma #catalent #pharma #solutions

#promius pharma # The power of humans being Every patient is a person first. Our desire to foster better health in all people is the driving force behind Promius Pharma. We celebrate all people, wherever they are on their journey, and they inspire us as we continue on ours. Together we can identify the opportunities in the spirit of innovation, by learning from real people as our blueprint for success. Together we may be able to do more to restore a patient’s spirit and get them back to what matters most—being a person. It’s simple—we work best when we work …

Aug 23 2017

Promius Pharma, LLC Company Information #cadila #pharma

#promius pharma # Promius Pharma, LLC Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page helpful? …

Aug 23 2017

Promius Pharma #gold #pharma

#promius pharma # The power of humans being Every patient is a person first. Our desire to foster better health in all people is the driving force behind Promius Pharma. We celebrate all people, wherever they are on their journey, and they inspire us as we continue on ours. Together we can identify the opportunities in the spirit of innovation, by learning from real people as our blueprint for success. Together we may be able to do more to restore a patient’s spirit and get them back to what matters most—being a person. It’s simple—we work best when we work …

Aug 23 2017

Promius Pharma Launches NoTime4Migraines, An Online Resource About Migraine Symptoms and Potential #pharma #kava

#promius pharma # Promius Pharma Launches NoTime4Migraines, An Online Resource About Migraine Symptoms and Potential Treatment Options PRINCETON, N.J. Aug. 24, 2016 /PRNewswire/ — Promius Pharma, LLC, today launched NoTime4Migraines. an online disease education resource for migraine patients that adds dimension to awareness with a social media presence on Facebook and Twitter . NoTime4Migraines helps patients recognize that their migraine attacks vary and offers ways to manage them. Its goal: empower patients to seek better control of migraine its symptoms and impact on everyday life at home, work, school, or in social settings. “Migraines are not just painful they can …

Aug 13 2017

Promius Pharma, LLC Company Information #pharmaceutical #reps

#promius pharma # Promius Pharma, LLC Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page helpful? …

Aug 13 2017

Promius Pharma Launches NoTime4Migraines, An Online Resource About Migraine Symptoms and Potential #exl #pharma

#promius pharma # Promius Pharma Launches NoTime4Migraines, An Online Resource About Migraine Symptoms and Potential Treatment Options PRINCETON, N.J. Aug. 24, 2016 /PRNewswire/ — Promius Pharma, LLC, today launched NoTime4Migraines. an online disease education resource for migraine patients that adds dimension to awareness with a social media presence on Facebook and Twitter . NoTime4Migraines helps patients recognize that their migraine attacks vary and offers ways to manage them. Its goal: empower patients to seek better control of migraine its symptoms and impact on everyday life at home, work, school, or in social settings. “Migraines are not just painful they can …